Healthcare Providers and Services
Company Overview of St. Michael's Hospital
St. Michael's Hospital owns and operates a hospital that provides healthcare services. It offers physical, emotional, and spiritual care services; onsite services; and specialized programs, clinics, inpatient care units, and professional services, as well as tests, laboratory, and imaging services. The company also operates a teaching and research hospital for students from nursing, research, medicine, and health disciplines. It partners with Hospital Collaborative on Vulnerable and Marginalized Populations, South East Toronto Organization, Health Equity Council, Women's College Hospital Uninsured Network, and Toronto Harm Reduction Task Force. St. Michael's Hospital was founded in 1892 and ...
30 Bond Street
Toronto, ON M5B 1W8
Founded in 1892
Key Executives for St. Michael's Hospital
Chief Executive Officer, President, and Director
President of St. Michael's Foundation
Chief Medical Officer and Executive Vice President
Chief Nursing Executive, Interim Chief Health Disciplines Executive, Executive Vice President of Programs, and Director
Vice President of Research
Compensation as of Fiscal Year 2016.
St. Michael's Hospital Key Developments
Edge Therapeutics Announces Multi-Year Research and Discovery Collaboration with St. Michael's Hospital
Nov 18 14
Edge Therapeutics announced a multi-year research and discovery collaboration with St. Michael's Hospital. The collaboration will focus on new therapeutic approaches for the treatment of various acute neurological conditions resulting from neurovascular instability. This discovery collaboration brings together Edge's scientific expertise in neurovascular disease with the research and high-throughput drug screening resources of St. Michael's Hospital. Initially the collaboration will focus on using validated models of intracerebral hemorrhage, cavernous malformations, and traumatic brain injury developed by St. Michael's to rapidly screen libraries of compounds for therapeutic activity, and to identify and optimize lead candidates for Edge's early stage pipeline. As previously announced, Edge Therapeutics has initiated patient enrollment in the third cohort of its NEWTON (Nimodipine microparticles to Enhance recovery While reducing TOxicity after subarachNoid hemorrhage) study, a multicenter, randomized, controlled, open-label, Phase 1/2 clinical trial of its lead product candidate EG-1962. The NEWTON study is evaluating the safety, tolerability and pharmacokinetics of EG-1962 compared to the current standard of care, oral nimodipine, in patients with aneurysmal subarachnoid hemorrhage (aSAH). Edge is also investigating a second compound, EG-1964, for prevention of recurrence of chronic subdural hematoma. The company plans to submit an IND for that treatment in 2015.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries